Understanding type 2 diabetes: symptoms and causes

Type 2 diabetes is a progressive metabolic disease in which your body develops insulin resistance, and the pancreatic beta cells can no longer compensate by producing extra insulin [1]. Unlike type 1, where the immune system destroys the beta cells, in type 2 they function defectively. They keep producing insulin, but not enough for your increased needs. It is like the difference between a destroyed factory (type 1) and one that runs poorly and cannot keep up with demand (type 2).

The fundamental differences include gradual onset over years (type 2) versus relatively abrupt onset over weeks (type 1), the presence of endogenous insulin versus its near-total absence, initial treatment with lifestyle changes and oral medications versus mandatory insulin from the very start, and partial reversibility in early stages (type 2) versus irreversibility in type 1 [1]. In type 2 you still have pancreatic reserve for years, you may never need insulin from outside if you control the disease well, and you do not risk the rapid onset of ketoacidosis when treatment is missed, as happens in type 1.

Insulin resistance develops when your muscle, liver, and fat cells respond insufficiently to the action of insulin, requiring ever higher insulin concentrations to achieve the same metabolic effect [2]. The accumulation of ectopic fat (in abnormal places) in muscle and liver interferes with the intracellular insulin signaling cascade, blocking the movement of glucose transporters to the cell membrane. Chronic low-grade inflammation, mediated by pro-inflammatory adipokines (TNF-α, IL-6), and oxidative stress disrupt the activation of insulin receptors [2].

The factors that amplify insulin resistance include an excess of circulating free fatty acids derived from increased lipolysis, mitochondrial dysfunction that reduces the cell's capacity to produce energy, and the accumulation of toxic lipid metabolites (ceramides, diacylglycerol) in insulin-sensitive tissues [1]. The initial compensatory hyperinsulinemia paradoxically worsens resistance even further through receptor down-regulation (a decrease in their number) and the gradual reduction in the number of beta cells, which are already working in overdrive. It is a vicious circle in which insulin requirements rise continuously until endogenous production becomes insufficient [2].

Type 2 diabetes cannot turn into type 1 because they are diseases with completely different pathogenetic mechanisms [1]. In type 2 we have insulin resistance with progressive beta cell dysfunction, whereas in type 1 there is autoimmune destruction of the beta cells. What may look like a "transformation" is in fact the natural progression of type 2 toward insulin dependence, after beta cell exhaustion, but the mechanism remains non-autoimmune. Alternatively, you may have LADA (a form of type 1 diabetes) misdiagnosed initially as type 2 because of its slow onset [3].

Approximately 2-12% of adults initially diagnosed with type 2 actually have LADA, which can be demonstrated by the presence of anti-GAD or anti-IA2 autoantibodies and a C-peptide level disproportionately low relative to the disease duration [3]. The confusion arises when lean patients with "type 2" progress rapidly toward needing insulin. These are often cases of LADA or even classic type 1 with adult onset. Testing for autoantibodies clarifies the diagnosis and has important prognostic implications, because LADA requires insulin earlier and does not respond durably to oral medication [3].

Type 2 diabetes can be put into remission through intensive lifestyle interventions or bariatric surgery, especially in the first years after diagnosis, when beta cell function is still recoverable [4]. The DiRECT study showed that losing more than 15 kg can induce remission in 86% of participants who have had diabetes for less than 6 years, maintained in 36% after 2 years [4]. Remission means an HbA1c below 6.5%, with no antidiabetic medication, for a minimum of 3 months, but it requires lifelong monitoring because the metabolic predisposition persists.

Reversibility depends on residual beta cell function, the duration of the diabetes, the degree of glucotoxicity and lipotoxicity, and your ability to maintain weight loss over the long term [5]. After 10 years of disease, the chances of remission drop below 5% because of the irreversible decline in the number of beta cells. Metabolic surgery can sometimes induce remission even in more advanced diabetes, through complex hormonal mechanisms that go beyond simple weight loss [6]. However, relapse occurs in half of patients within the next 5 years, especially if eating habits return to the previous pattern [6].

Residual insulin production in type 2 diabetes means that the pancreatic beta cells are still secreting insulin, which can be demonstrated by a positive C-peptide (above 1 ng/ml) [7]. Unfortunately, the amount and the pattern of secretion are insufficient for the body's normal metabolism. The first phase of insulin secretion (the first 5 minutes after a stimulus) is lost early, and basal secretion becomes insufficient to keep hepatic glucose production in check [1]. There is measurable circulating insulin (often even elevated at first), but its effect is diminished by tissue resistance.

The presence of endogenous insulin gives you major advantages over type 1. You have protection against ketoacidosis (residual insulin inhibits massive lipolysis), flexibility in the timing of meals and medication, a response to oral medications that stimulate or sensitize the body to the action of insulin, and lower glycemic variability [7]. Periodic monitoring of C-peptide helps assess beta cell reserve and guides the need to intensify therapy. In general, when C-peptide drops below 0.6 ng/ml, achieving metabolic control with oral medications alone becomes very difficult [7].

The progression of type 2 diabetes follows a trajectory of declining beta cell function of about 5% per year after diagnosis, eventually accelerated by persistent gluco- and lipotoxicity [1]. Initially, compensatory hyperinsulinemia keeps blood glucose within target, then postprandial hyperglycemia appears when the first phase of secretion is lost, followed by fasting hyperglycemia when hepatic glucose production can no longer be suppressed. After 15 years, more than half of patients require injectable treatment added to oral therapy [8].

Microvascular complications (retinopathy, chronic kidney disease, neuropathy) may already be present at diagnosis in 20% of cases, because of the long asymptomatic period, and they progress exponentially with suboptimal glycemic control [9]. Cardiovascular risk is at least double, independent of other factors, and every 1% rise in HbA1c increases the risk of microvascular complications by 37% and of myocardial infarction by 14% [10]. Early intensive interventions can modify the natural trajectory. The "metabolic memory" phenomenon shows persistent benefits 10-20 years after a period of tight control in the first years following diagnosis [11].

The outdated term "non-insulin-dependent" (NIDDM) reflected the observation that most patients with type 2 can survive without exogenous insulin, unlike type 1, where stopping insulin rapidly leads to ketoacidosis and death [8]. The classification was abandoned in 1997 because it was misleading. Up to 40% of patients with type 2 eventually require insulin treatment for optimal glycemic control, and some need it right from diagnosis [8]. The term wrongly implied that insulin is never necessary and delayed its initiation when it became medically indicated.

The current etiology-based name (type 2 = a secretory deficit with variable insulin resistance) is more precise and guides treatment [1]. "Non-insulin-dependent" ignored the heterogeneity of the disease. Some patients have predominantly insulin resistance with hyperinsulinemia, others have a predominant secretory deficit with normal or low insulin levels. Using the old term can delay starting insulin when it becomes necessary, perpetuating suboptimal glycemic control and accelerating complications. In modern terms, we speak of "type 2 diabetes treated with/without insulin" to describe the current stage of disease management [8].

The incidence of type 2 diabetes rises exponentially with age, peaking at 65 years, when it affects 25% of the population (prevalence) in developed countries [8]. The age at diagnosis is steadily falling. Compared with the 1990s, the diagnosis is now made at least five years earlier [12]. After 65 years, prevalence exceeds 30%, and beyond 80 years it can reach 40%, although phenotypic heterogeneity increases with age, including forms of pancreatogenic or drug-induced secondary diabetes.

Alarmingly, type 2 diabetes in young people (under 40 years) has nearly doubled over the past two decades, now accounting for one-fifth of new cases in some populations [12]. Early onset is associated with faster progression of beta cell dysfunction, a higher risk of microvascular complications, and premature mortality [13]. Children and adolescents with type 2 diabetes have a more aggressive phenotype than adults. They need insulin sooner (within 5-10 years), develop complications 10-15 years earlier, and have a life expectancy reduced by up to 15 years compared with adult-onset disease [13].

Beta cell exhaustion is the progressive and irreversible decline of insulin secretory capacity through multiple mechanisms [14]. Beta cell mass sometimes falls by 50% between the onset of the disease and diagnosis (which is made with a long delay), and it then continues to fall by 5% per year [15].

The process begins with the loss of the normal pulsatile secretion pattern and of the first phase of insulin secretion in response to glucose [1]. It then progresses to an inability to suppress hepatic glucose production and eventually to complete failure requiring exogenous insulin. Markers of exhaustion include an increased proinsulin/insulin ratio (an indicator of defective processing), a C-peptide below 0.6 ng/ml under stimulation, and the presence of islet amyloid deposits, which are toxic to the beta cells [15]. Once lost, adult beta cells have minimal regeneration capacity, making the process practically irreversible once a certain critical mass has been lost [14].

Type 2 diabetes accounts for 90% of all cases of diabetes mellitus [8]. Its prevalence has risen dramatically over the past four decades. In developed countries, prevalence is around 10% of the entire adult population, but it can exceed 30% in people over 65 years [8]. The lifetime risk of developing type 2 diabetes ranges from 30-40% in Western countries, rising to 40% for those with one diabetic parent and to 70% when both parents have diabetes.

Frequency rises exponentially with age, obesity, and a sedentary lifestyle, being three times higher in people with a body mass index over 30 kg/m² [8]. There are significant ethnic differences, with rates at least double in populations from South Asia, the Middle East, Africa, and Latin America compared with Caucasians. Millions of people have type 2 diabetes that is still undiagnosed. Globally, almost half (45%) of those affected do not know they have the disease, with the proportion falling to about 30% in developed countries [8]. The incidence in children and adolescents has nearly doubled over the past two decades, a phenomenon linked to the childhood obesity epidemic [12].